Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 601 to 615 of 2854 results for process

  1. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  12 August 2026

    NICE guideline
    In development

  2. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development Reference number: GID-TA10250 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  6. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  17 June 2026

    NICE guideline
    In development

  7. Autism: register (IND175)

    This indicator covers establishing and maintaining a register of all patients on the autistic spectrum. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM153

    General practice indicators suitable for use in QOF
    Published
    31 July 2017

  8. Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service provision should be carried out to identify factors affecting outcomes. Factors should include whether care is provided in a dedicated unit, staffing configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related outcomes. Data collected should be used to analyse the cost effectiveness of early pregnancy assessment units compared with other models of care.

    configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related...

    Research recommendation
    Published
    17 December 2021

  9. NICE content assurance service

    NICE content assurance service

  10. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]

    Awaiting development Reference number: GID-TA11059 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development